Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Baboon Study Suggests Cancer-Related Genes Regulate LDL Cholesterol Levels

By BiotechDaily International staff writers
Posted on 30 May 2013
Image: Senior author Dr. Laura A. Cox (Photo courtesy of Texas Biomedical Research Institute).
Image: Senior author Dr. Laura A. Cox (Photo courtesy of Texas Biomedical Research Institute).
Genome analysis of baboons in a controlled feeding study identified four genes linked to control of the level of serum low-density lipoprotein cholesterol (LDL-c), a biomarker for risk of cardiovascular disease.

Investigators at the Texas Biomedical Research Institute (San Antonio, USA) had previously identified a cluster of quantitative trait loci (QTL) on baboon chromosome 11 for multiple related quantitative traits for serum LDL-c. In the current study, they determined the level of LDL-c in the 1,500 animals in their baboon colony and selected three baboons with low LDL-c levels and three with high levels. The baboons were fed a high-cholesterol, high fat (HCHF) diet for seven weeks, after which hepatic whole genome expression profiling for LDL-c was performed.

Results published in the April 17, 2013, online edition of the Journal of Lipid Research revealed that three genes were differentially expressed in the low LDL-c animals and eight in high LDL-c animals in response to the HCHF diet. Seven genes (ACVR1B, CALCOCO1, DGKA, ERBB3, KRT73, MYL6B, and TENC1) showed discordant expression between the low and high LDL-c baboons.

Data obtained with gene array and high throughput sequencing technology enabled integration of microRNA (miRNA) and messenger RNA (mRNA) expression profiles, which showed that four candidate genes (ACVR1B, DGKA, ERBB3, and TENC1) were miRNA targets and that the miRNAs were inversely expressed to the target genes. The four genes are members of a signaling pathway known to be important for cell survival, and disruption of this pathway due to mutations in these genes has been associated with some types of cancer.

"Our findings are important because they provide new targets for the development of novel drugs to reduce heart disease risk in humans," said senior Dr. Laura Cox, associate scientist in genetics at the Texas Biomedical Research Institute. "Since these genes have previously been associated with cancer, our findings suggest that genetic causes of heart disease may overlap with causes of some types of cancer. That starts to give us the specific targets for new therapies. If all goes well, this information may be available within two years."

Related Links:
Texas Biomedical Research Institute


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.